Citrulline Efficacy to Improve Carbohydrate Metabolism Abnormalities in the Patient Treated With High Doses of Statin

Inclusion criteria

• 40 years old < Age <75 years old
• men and women who are menopausal or who benefit from effective contraception
• treatment with atorvastatin at 40 or 80 mg / d for more than 3 months for primary prevention or secondary prevention at more than 3 months of the acute event (stroke, acute coronary syndrome) with or without ezetimibe (Ezetrol® monotherapy or in the form of associated with atorvastatin Liptruzet® 10/40 or 10/80)
• with a Body Mass Index (BMI) ≥28 kg / m2 and at least one other risk factor for statin-dependent diabetes among the following 4:

• Blood pressure ≥ 140/90 mmHg or hypotensive treatment
• Triglyceridemia ≥ 150 mg / l
• Fasting blood glucose ≥ 100 mg / dl
• HDL-cholesterol <40 mg / dL in men, <50 mg / dL in women
• affiliated to a social security scheme
• signed informed consent

Exclusion criteria

• General criteria:

• Subject with unstable medical or psychological conditions that, in the opinion of the investigator, could lead the subject to be non-compliant or uncooperative during the study or could compromise the safety or participation of the subject under study L.1121-6, L.1121-8, L.1121-9 and L1122-1-2 of the Public Health Code).
• Major subjects under guardianship or deprived of their liberty by judicial or administrative decision.
• Plan for weight loss during the previous 3 months, current or future
• Dietary supplements for weight loss (based on plant extracts, algae, pre- and probiotics) in the previous 3 months or in progress

Biological criteria:

• Aspartate Amino Transferase (ASAT), Alanine Amino Transferase (ALAT)> 2 times the normal values
• HbA1c> 6.5%
• Creatin Phospho Kinase (CPK)> 2 times normal
• Triglycerid > 5g / L
• Renal insufficiency (clearance <60 mL / min)
• Demonstration of a biological abnormality deemed by the investigator to be clinically significant

Medical and therapeutic criteria:

• Diabetes type 1 or 2
• Subjects treated with a drug that may interfere with the metabolism of citrulline and glucose (vitamin K antagonists, corticosteroids for more than 8 days before the study, anorexigenic drugs (Anorex, Fenproporex Deglaude AP, Moderatan, Prefamone Chronules), drugs (Orlistat, Lioresal)
• Any associated or uncontrolled progressive pathology (cardiac pathology, myocardial infarction of less than 6 months, arterial hypertension, psychiatric, renal or hepatic, cancer).
• pregnant or lactating woman
• Consumption of more than 3 glasses of alcohol per day.
• Subjects who express any reluctance to consume a food supplement morning and evening.
• eating disorders.
• Weight variation of +/- 5% during the previous 3 months
• Severe, progressive affection.
• Depressive or psychiatric state (antidepressant or psychotropic treatment).
• Medical or surgical history deemed by the investigator to be incompatible with this study.
• Blood donation in the 2 months prior to inclusion.